featured
ESMO 2018: Localizing Pathologic Response After Neoadjuvant Immunotherapy for Stage III Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: